Rapport Therapeutics (RAPP) News Today $23.93 +0.63 (+2.70%) (As of 07/5/2024 ET) Add Share Share HeadlinesStock AnalysisAnalyst ForecastsChartInsider TradesTrendsStock AnalysisAnalyst ForecastsChartInsider TradesTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative July 5 at 4:01 PM | insidermonkey.comHedge Fund and Insider Trading News: Bill Ackman, Segantii Capital Management Ltd, Rapport Therapeutics Inc (RAPP), Archer Aviation Inc (ACHR), and MoreJuly 5 at 11:29 AM | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Shares Gap Up to $23.30Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up to $23.30July 4 at 8:20 AM | insidertrades.comJames Healy Purchases 44,032 Shares of Rapport Therapeutics (NASDAQ:RAPP) StockJuly 3 at 10:13 PM | marketbeat.comJames Healy Acquires 44,032 Shares of Rapport Therapeutics (NASDAQ:RAPP) StockRapport Therapeutics (NASDAQ:RAPP - Get Free Report) Director James Healy acquired 44,032 shares of the stock in a transaction dated Monday, July 1st. The stock was bought at an average price of $24.52 per share, for a total transaction of $1,079,664.64. Following the completion of the purchase, the director now owns 40,851 shares in the company, valued at approximately $1,001,666.52. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.July 3 at 4:46 AM | americanbankingnews.comRapport Therapeutics (NASDAQ:RAPP) Coverage Initiated by Analysts at TD CowenJuly 3 at 3:29 AM | americanbankingnews.comRapport Therapeutics (NASDAQ:RAPP) Receives New Coverage from Analysts at Stifel NicolausJuly 2 at 8:20 AM | americanbankingnews.comRapport Therapeutics (NASDAQ:RAPP) Research Coverage Started at Jefferies Financial Group Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden to drop out; finish out his term? (Ad)On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election. See who it is HERE. RAPP Media Mentions By Week RAPP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RAPP News Sentiment▼0.970.66▲Average Medical News Sentiment RAPP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RAPP Articles This Week▼90▲RAPP Articles Average Week Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RAPP) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored7 Great Summertime Stock Plays for YouWe’ve got seven great summertime plays for you. These stocks are in a prime position to reward your portfolio…...StockEarnings | SponsoredUrgent alert: open this for a huge profit potentialThis groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
